1. Volume 148, Issue 3, Pages 483-487 (March 2015)
Guanylate Cyclase C Agonists: Emerging Gastrointestinal Therapies and Actions 
Michael Camilleri 
Gastroenterology 
Volume 148, Issue 3, Pages (March 2015)
DOI: /j.gastro
Copyright © 2015 AGA Institute Terms and Conditions

2. Figure 1
Amino acid structures of stable toxin and its analog, linaclotide, and guanylin, uroguanylin, and its analog, plecanatide. The cysteine residues are shown by the different color of the amino acid and by the disulfide bonds, indicated by the square brackets.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions

3. Figure 2
Intracellular mediators and actions resulting from the effects of GC-C ligands. The production of cyclic guanosine monophosphate (cGMP) results in chloride secretion through cystic fibrosis transmembrane conductance regulator (CFTR) as well as down-regulation of cytokines, enhancement of mucosal barrier function, apoptosis, and visceral analgesia. These actions are potentially relevant for intestinal diseases associated with constipation, abdominal pain, inflammation and neoplasia or pre-neoplastic conditions. IL, interleukin; GC-C, guanylate cyclase C; PDE, phosphodiesterase; TNF, tumor necrosis factor.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2015 AGA Institute Terms and Conditions